Why This, Why Now?

Three things explain most of what looks, from the outside, like a uniquely Canadian problem with funding and talent. None of them are unique to Canada, and none of them are new — they're well-documented behavioral and organizational psychology, including Geert Hofstede's research on national uncertainty avoidance, and one of the most rigorously studied frameworks in organizational psychology. What's specific to this work is applying them, rigorously, to where Canadian health innovation actually breaks down. And what's incomplete about applying them alone is that culture isn't the only place it breaks down — capital and policy break down right alongside it, for reasons that have nothing to do with psychology at all.

Culture

Behavioral economists call this status quo bias — the well-documented tendency to default to no action at all, even when the benefit of acting is clearly visible. It doesn't require fear or malice. It simply requires that the existing system pushes hard enough against the friction of changing it.

In Canadian healthcare and life sciences, this pattern is everywhere and hiding in plain sight. Canadian hospitals still admit and refer patients out for lab work — not because it's more accurate, efficient, or effective, but because every already-invested workflow shifts with agonizing slowness once it's been overbuilt around legacy systems. Physicians document around their genuine workflow needs. Formularies — the lists of drugs and treatments approved for use — lag behind even where clear clinical advantage demonstrates the burden of proof required to displace an existing standard of care is vastly higher than the burden required to keep it.

Social psychologists have studied this since the 1960s, when Latané and Darley documented what became the bystander effect: as the number of people who could plausibly act on a problem grows, each individual becomes less likely to be the one who does. In Canadian health innovation, diffusion of responsibility is the default architecture, not an edge case. A genomics startup spends three years in Ontario's REB approval, waits eighteen months for a health-worker regulatory pathway, and clears Health Canada review — and then stalls, not because anyone's mandate ended, but because nobody's mandate ever explicitly began at the handoff.

Decision scientists have long documented a related asymmetry. Kahneman and Tversky's Prospect Theory established that a loss of a given size is felt roughly twice as powerfully as an equivalent gain — the psychological weight of a visible mistake outweighing the invisible cost of inaction. In Canadian health systems specifically, this becomes a cultural operating system: a hospital chooses inaction over a five-percent chance of an adverse headline, even when that inaction predictably produces worse outcomes in aggregate. Regulatory bodies face identical pressure — no equivalent scrutiny exists for approving treatments too slowly as exists for approving them too fast.

None of these are decisions made by careless people. They're the entirely predictable output of a system where inaction is invisible and action requires effort, coordination, and someone willing to absorb the friction of being the one who pushed for change.

Capital

Culture explains why a good idea stalls inside an organization. It doesn't explain why a company that's already cleared every internal hurdle — proven the science, proven the market — still can't find the capital to stay Canadian while it scales.

Canadian life sciences venture funds average $150–300 million and typically write $10–20 million cheques: enough to carry a company through early rounds, far short of what a late-stage scale-up actually needs. Federal matching programs meant to close that gap instead fragment public capital into allocations too small for any single fund to lead a real round. And Canada's own pension funds — which actively co-invest in life sciences growth deals abroad — allocate only a fraction of that appetite domestically, not for lack of returns, but because no Canadian vehicle is large enough to absorb a pension-scale cheque. The predictable result: promising Canadian companies take the capital that's actually available, and the capital that's available usually comes with a relocated headquarters attached.

This is the moment economists call the valley of death, and in Canadian life sciences it isn't one valley but two. The first sits between a university lab and a fundable company, where commercialization dollars have historically routed through the wrong institutional structures to reach the specialized talent that scaling a company actually requires. The second sits later, once the science and the market are both already proven, when the only capital deep enough to fund the next round comes from outside the country — arriving with a term sheet that assumes the headquarters, the IP, and the decision-making move with it. A company that survives the first valley only to lose the business at the second isn't a failure of Canadian science. It's a predictable failure of Canadian capital markets, repeating itself company after company, cheque after cheque.

Policy

Underneath both is a tax and regulatory system that was never built to recycle capital, or urgency, back into the next generation of Canadian companies. Public research funding like SR&ED and IRAP subsidizes early discovery with no mechanism tying that investment to where the resulting company, IP, or manufacturing ultimately lands. Procurement systems score bids on upfront unit cost, while the savings an innovative technology generates downstream land in a completely different budget than the one that paid for it. These aren't oversights — they're policy built for a different era of the problem, and they're specific enough to name and fix.

The same pattern shows up in how Canada treats a successful exit. When a founder or an early investor takes a win, the tax system offers little incentive to put that capital back into the next Canadian company — so it often leaves the ecosystem entirely, chasing the next opportunity wherever the after-tax return is highest. Compare that to how Canada already treats the film industry, where a targeted tax incentive proved decades ago that private capital will move quickly into a domestic sector when the after-tax math rewards it. Life sciences has never been offered the equivalent. Every recommendation in this work — from a domestic capital gains framework to a statutory pension mandate — is aimed at the same target: making it more profitable, after tax, to build the next Canadian company than to sell this one.

Three Decades. Experience From Every Angle.

Natalie Yeadon started her career as a radiation therapist, treating cancer patients, then spent eighteen years in pharmaceutical marketing and commercialization — including bringing Herceptin and IRESSA to the Canadian market — before she built, scaled, and exited Impetus Digital, a bootstrapped Canadian technology platform, after sixteen years.

She's now researching and writing Breaking Innovation Paralysis, drawing on direct experience of a country with world-class discovery research and severely underfunded pathways to get those innovations to the people who need them. Her policy work has included a formal pre-budget submission to the House of Commons Standing Committee on Finance, and she's a candidate in the Council of Canadian Innovators' Innovation Governance Program.

Stagnation Culture

Why systems--people, companies, governments--keep choosing inaction, or the wrong action, even when they know better.

2026 Augmentios. All Rights Reserved.

Privacy Policy

Terms and Conditions